

Nivolumab + ipilimumab CheckMate 227

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects




Other adjustments



Nivolumab + ipilimumab CheckMate 227

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: First-line treatment for patients with mNSCLC expressing PD-L1 ($\geq 1\%$) with no EGFR or ALK genomic tumour aberrations
Experimental Arm: Nivolumab + ipilimumab
Control Arm: Chemotherapy

